Cardinal Health announced that its Lymphoseek radiopharmaceutical has been approved for pediatric use by the U.S. Food and Drug Administration (FDA).
This comes after a clinical trial showed the radiopharmaceutical was deemed "safe and effective" for patients ages one month and older.
In addition to adult use, Lymphoseek provides lymph node identification in pediatric patients with melanoma, rhabdomyosarcoma (RMS), or other types of solid tumors. The approval will offer physicians, oncologists, and nuclear medicine specialists an option to enhance lymphatic mapping and guide sentinel lymph node biopsies in pediatric melanoma cases.
